Kevin Jackson, MD
Internal Medicine · Opelika, ALNPI 1316938517
Payments from drug & device makers
Across 107 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$296
- Astellas Pharma US Inc$268
- Novo Nordisk$135
- Lilly USA, LLC$116
- Boehringer Ingelheim$113
- Amarin Pharma, Inc.$108
- plus $890 from 26 others
What the payments were for
- Food & beverage$1,67187%
- Education$25413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 18 | $296 |
| Astellas Pharma US Inc | 4 | $268 |
| Novo Nordisk | 8 | $135 |
| Lilly USA, LLC | 8 | $116 |
| Boehringer Ingelheim | 9 | $113 |
| Amarin Pharma, Inc. | 7 | $108 |
| AbbVie(2 entities) | 5 | $92 |
| Johnson & Johnson | 5 | $76 |
| Novartis | 5 | $75 |
| Boston Scientific | 3 | $65 |
| Merck | 4 | $61 |
| Amgen | 3 | $53 |
| AstraZeneca | 3 | $53 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Exact Sciences | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Idorsia Pharmaceuticals US Inc | 2 | $34 |
| Radius Health, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Vistapharm, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Metacel Pharmaceuticals LLC | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Biogen | 1 | $13 |
| GSK | 1 | $13 |
| Athena Bioscience, LLC | 1 | $11 |
How this compares
$1,925 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 190 | $252,997 |
| OzempicSemaglutide | 162 | $173,766 |
| EliquisApixaban | 198 | $173,029 |
| JardianceEmpagliflozin | 104 | $89,859 |
| MyrbetriqMirabegron | 98 | $57,549 |
| FarxigaDapagliflozin Propanediol | 54 | $57,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $51,678 |
| JanuviaSitagliptin Phosphate | 52 | $49,805 |
| GemtesaVibegron | 39 | $30,344 |
| LinzessLinaclotide | 30 | $28,701 |
| CreonLipase/Protease/Amylase | 11 | $21,833 |
| Repatha SureclickEvolocumab | 29 | $17,528 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $16,034 |
| EntrestoSacubitril/Valsartan | 14 | $15,376 |
| Levothyroxine Sodium | 835 | $14,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $116 | $252,997190 claims |
| Novo NordiskOzempic | $135 | $173,766162 claims |
| PfizerEliquis | $296 | $173,029198 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $113 | $106,457138 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $13 | $67,711107 claims |
| Astellas Pharma US IncMyrbetriq | $268 | $57,54998 claims |
| AstraZenecaFarxiga | $53 | $57,30154 claims |
| AbbVieLinzess, Creon | $92 | $50,53441 claims |
| MerckJanuvia | $61 | $49,80552 claims |
| NovartisEntresto | $75 | $15,37614 claims |
| Johnson & JohnsonXarelto | $76 | $13,13418 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $17 | $6,05812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Opelika
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.